Patrick Verschueren

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.6K citations · Full text

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · 285 citations · Full text

Technical and Diagnostic Performance of 6 Assays for the Measurement of Citrullinated Protein/Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis

Dries Coenen, Patrick Verschueren, René Westhovens et al. · Clinical Chemistry · 2007 · 170 citations · Full text

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Kim Lauper, Michele Iudici, Denis Mongin et al. · Annals of the Rheumatic Diseases · 2022 · 138 citations · Full text

Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone

Patrick Durez, Jacques Malghem, A. Nzeusseu Toukap et al. · Arthritis & Rheumatism · 2007 · 124 citations